Current treatment landscape of HR+/HER2- advanced breast cancer in the Nordics: a modified Delphi study

DISCUSSION: ET in combination with a CDK4/6 inhibitor is the preferred frontline treatment for HR+/HER2- aBC in the Nordics. The observed discrepancy between current guidelines and clinical practice could be due to differences in the reimbursement of novel treatments in the Nordics. Collaborative research efforts are warranted for topics that lack consensus.PMID:37713138 | DOI:10.1080/0284186X.2023.2254475

Source: Acta Oncologica - September 15, 2023 Category: Cancer & Oncology Authors: J ürgen Geisler Peeter Karihtala Malgorzata Tuxen Antonis Valachis Delphi Panellist Group Barbro Holm Source Type: research